| Overview |
| bs-17162R-FITC |
| TPA Polyclonal Antibody, FITC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat, Dog, Cow, Sheep, Pig |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Tissue-type plasminogen activator chain B |
| 401-500/562 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5327 |
| P00750 |
| Secreted |
| TPA Tissue Plasminogen Activator; Alteplase; DKFZp686I03148; Plasminogen activator tissue; Plasminogen activator tissue type; PLAT; Reteplase; t PA; T Plasminogen Activator; t-PA; T-plasminogen activator; Tissue plasminogen activator (t PA); Tissue type plasminogen activator; Tissue-type plasminogen activator chain B; tPA; TPA_HUMAN; TPA1. |
| This gene encodes tissue-type plasminogen activator, a secreted serine protease which converts the proenzyme plasminogen to plasmin, a fibrinolytic enzyme. Tissue-type plasminogen activator is synthesized as a single chain which is cleaved by plasmin to a two chain disulfide linked protein. This enzyme plays a role in cell migration and tissue remodeling. Increased enzymatic activity causes hyperfibrinolysis, which manifests as excessive bleeding; decreased activity leads to hypofibrinolysis which can result in thrombosis or embolism. Alternative splicing of this gene results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008] |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz